[
    [
        {
            "time": "",
            "original_text": "孙飘扬、陈启宇、吕明方往一个城墙口冲锋：中国药企进军世界前列的准备、挑战、时间",
            "features": {
                "keywords": [
                    "孙飘扬",
                    "陈启宇",
                    "吕明方",
                    "中国药企",
                    "世界前列"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "孙飘扬、陈启宇、吕明方往一个城墙口冲锋：中国药企进军世界前列的准备、挑战、时间",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "A股明日风口：资本市场深改12条出台 外资限购令取消",
            "features": {
                "keywords": [
                    "A股",
                    "资本市场深改",
                    "外资限购令取消"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "资本"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股明日风口：资本市场深改12条出台 外资限购令取消",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "核心资产的下一站：大中型科技股",
            "features": {
                "keywords": [
                    "核心资产",
                    "科技股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "核心资产的下一站：大中型科技股",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "营收百亿药企大比拼：恒瑞、复星、上药",
            "features": {
                "keywords": [
                    "营收百亿",
                    "恒瑞",
                    "复星",
                    "上药"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "营收百亿药企大比拼：恒瑞、复星、上药",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "PD-1市场价格战燃起 红海之中谁能掌握先机？",
            "features": {
                "keywords": [
                    "PD-1",
                    "市场价格战",
                    "红海"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "PD-1市场价格战燃起 红海之中谁能掌握先机？",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-09-08",
            "original_text": "【山证医药】医药行业周报（20190908）：建议持续关注医保目录谈判与“4+7”带量采购扩面",
            "features": {
                "keywords": [
                    "医药行业",
                    "医保目录谈判",
                    "4+7带量采购"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【山证医药】医药行业周报（20190908）：建议持续关注医保目录谈判与“4+7”带量采购扩面",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "科技板块领跑A股 首只科技ETF规模激增近250%",
            "features": {
                "keywords": [
                    "科技板块",
                    "A股",
                    "科技ETF",
                    "规模激增"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "科技板块领跑A股 首只科技ETF规模激增近250%",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报:建议持续关注医保目录谈判与“4+7”带量采购扩面",
            "features": {
                "keywords": [
                    "医药行业",
                    "医保目录谈判",
                    "4+7带量采购"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报:建议持续关注医保目录谈判与“4+7”带量采购扩面",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "医药行业半年报业绩综述:内部仍在分化,龙头业绩亮眼",
            "features": {
                "keywords": [
                    "医药行业",
                    "半年报",
                    "业绩分化",
                    "龙头业绩"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业半年报业绩综述:内部仍在分化,龙头业绩亮眼",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]